[go: up one dir, main page]

MX2023011645A - Materiales y métodos para la redirección de células efectoras inmunitarias. - Google Patents

Materiales y métodos para la redirección de células efectoras inmunitarias.

Info

Publication number
MX2023011645A
MX2023011645A MX2023011645A MX2023011645A MX2023011645A MX 2023011645 A MX2023011645 A MX 2023011645A MX 2023011645 A MX2023011645 A MX 2023011645A MX 2023011645 A MX2023011645 A MX 2023011645A MX 2023011645 A MX2023011645 A MX 2023011645A
Authority
MX
Mexico
Prior art keywords
molecules
cell
molecule
redirection
materials
Prior art date
Application number
MX2023011645A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Xiefan Lin-Schmidt
Jason Ho
Adam Zwolak
Ian White
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023011645A publication Critical patent/MX2023011645A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una molécula que comprende un primer medio para acoplar o activar una célula destructora natural (NK), y un segundo medio para unirse a una célula tumoral, en donde la molécula es capaz de inducir la citotoxicidad dependiente de células NK contra la célula tumoral.
MX2023011645A 2021-03-31 2022-03-30 Materiales y métodos para la redirección de células efectoras inmunitarias. MX2023011645A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163168605P 2021-03-31 2021-03-31
US202163168618P 2021-03-31 2021-03-31
US202163168611P 2021-03-31 2021-03-31
US202163168628P 2021-03-31 2021-03-31
US202163168621P 2021-03-31 2021-03-31
PCT/US2022/022500 WO2022212470A2 (en) 2021-03-31 2022-03-30 Materials and methods for immune effector cells redirection

Publications (1)

Publication Number Publication Date
MX2023011645A true MX2023011645A (es) 2023-12-14

Family

ID=83459998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011645A MX2023011645A (es) 2021-03-31 2022-03-30 Materiales y métodos para la redirección de células efectoras inmunitarias.

Country Status (11)

Country Link
US (1) US20240182582A1 (es)
EP (1) EP4314080A4 (es)
JP (1) JP2024512135A (es)
KR (1) KR20230163485A (es)
AU (1) AU2022246607A1 (es)
BR (1) BR112023020249A2 (es)
CA (1) CA3214963A1 (es)
IL (1) IL307312A (es)
MX (1) MX2023011645A (es)
TW (1) TW202304992A (es)
WO (1) WO2022212470A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
TW202523698A (zh) 2023-07-31 2025-06-16 法商賽諾菲公司 抗ｇｐｒｃ５ｄ抗體及組成物
US20250188163A1 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Gprc5d antibodies with enhanced effector function and uses thereof
WO2025137555A1 (en) * 2023-12-20 2025-06-26 Omniab, Inc. Polypeptides that bind to nkp46

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
CN104994872B (zh) * 2012-06-21 2018-09-14 索伦托治疗有限公司 与igf1r结合的抗原结合蛋白
US11227669B2 (en) * 2014-06-21 2022-01-18 Norbert Ikechukwu Nwankwo Computer aided drug resistance calculator calculating drug resistance using amprenavir as a case study
KR20210019491A (ko) * 2016-03-23 2021-02-22 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
AU2018219348A1 (en) * 2017-02-10 2019-08-29 Dragonfly Therapeutics, Inc. Proteins binding BCMA, NKG2D and CD16
AU2019220395B2 (en) * 2018-02-14 2025-12-04 Abba Therapeutics Ag Anti-human PD-L2 antibodies
US20210009711A1 (en) * 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US12077585B2 (en) * 2019-07-26 2024-09-03 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
PE20220394A1 (es) * 2019-07-31 2022-03-18 Hoffmann La Roche Anticuerpos que se fijan a gprc5d

Also Published As

Publication number Publication date
US20240182582A1 (en) 2024-06-06
CA3214963A1 (en) 2022-10-06
JP2024512135A (ja) 2024-03-18
EP4314080A2 (en) 2024-02-07
TW202304992A (zh) 2023-02-01
KR20230163485A (ko) 2023-11-30
IL307312A (en) 2023-11-01
WO2022212470A9 (en) 2023-04-13
BR112023020249A2 (pt) 2023-12-19
WO2022212470A2 (en) 2022-10-06
WO2022212470A3 (en) 2022-11-17
EP4314080A4 (en) 2025-06-04
AU2022246607A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2023011645A (es) Materiales y métodos para la redirección de células efectoras inmunitarias.
CY1124453T1 (el) Πολυπεπτιδια που περιεχουν επικρατειες προσδεσης de novo και χρησεις αυτων
AR120936A1 (es) Anticuerpos anti-cd73 y usos de estos
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
BR112023019138A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
EA201891127A1 (ru) Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
CO2020001654A2 (es) Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
AR126625A1 (es) Vacunas de arn
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
AR119902A1 (es) Proteínas de fusión terapéuticas
MX2023001083A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
BR112023025331A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
ZA202304872B (en) Anti-sclerostin constructs and uses thereof
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
BR112021017486A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017464A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017479A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017467A2 (pt) Receptores de células t e métodos de uso dos mesmos
CO2023016037A2 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
MX2022001209A (es) Receptores de linfocitos t y métodos de uso de estos.